Sign inCreate account

Report workspace tools

NCT04495088RECRUITINGanonymous

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group

Sponsor

Source record

Ralf Hofheinz

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Indication / condition

AI-normalized

Rectal Cancer

Intervention

Source record

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Source & freshness

Source record

NCT ID

NCT04495088

Original source

ClinicalTrials.gov

Source last updated

Feb 02, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04495088

Title

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group

Sponsor

Ralf Hofheinz

Status

RECRUITING

Phase

PHASE3

Condition raw

Rectal Cancer

Condition normalized

Rectal Cancer

Modality raw

small molecule

Modality normalized

small molecule

Target raw

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Target normalized

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Interventions

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Public preview

Source record

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer and Low Risk for Local Failure: A Randomized Phase III Trial of the German Rectal Cancer Study Group

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04495088

Status

RECRUITING

Phase

PHASE3

Sponsor

Ralf Hofheinz

Executive brief

Investment-Ready Snapshot

This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 02, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04495088

Indication

Rectal Cancer

Modality

small molecule

Target

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Intervention

mFOLFOX (neoadjuvant), XELOX (neoadjuvant), mFOLFOX (adjuvant), XELOX (adjuvant), Capecitabine (adjuvant), infusional 5-FU/FA "AIO" regimen (adjuvant), infusional 5-FU/FA "de Gramont" (adjuvant)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.